Sionna Therapeutics, Inc. (SION) Stock Score, Valuation & Financial Research

Sionna Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SION

Sionna Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 5.11. These figures are a research snapshot, not a buy or sell recommendation.

What Sionna Therapeutics, Inc. does

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Sionna Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or commercialization of its pipeline of small-molecule CFTR modulators designed to treat cystic fibrosis.

Products and services

  • The company is developing a pipeline of small-molecule CFTR modulators, including NBD1 stabilizers such as SION-719 and SION-451, intended to treat the underlying causes of cystic fibrosis.

Brands and product families

  • SIONNA — Corporate brand and trademark. Source

Customer types

Patients with cystic fibrosis.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract research organizations and contract manufacturing organizations for the development, clinical trial management, and manufacturing of its drug candidates. Specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Vertex Pharmaceuticals Incorporated — A company that develops and markets approved CFTR modulators for the treatment of cystic fibrosis. Source

Business strengths to evaluate

  • Proprietary CFHBE model for clinical prediction Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on success of clinical-stage product candidates Source
  • Reliance on third-party manufacturers and clinical trial providers Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SION financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.11
Market capitalization:
230.72M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -97.38M
Free cash flow:
USD -66.67M
Cash:
USD 63.32M
Total debt:
USD 8.07M
EPS:
USD -2.18

What stands out

  • Free cash flow is USD -66.67M, negative for the stored period.
  • The balance sheet shows USD 63.32M of cash versus USD 8.07M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 55.25M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SION

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SION fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SION likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SION to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of SION's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research SION

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.